Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis

Studies of Ocular Complications of AIDS (SOCA) Research Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Filgrastim, or granulocyte colony-stimulating factor, reverses neutropenia associated with human immunodeficiency virus type 1 (HIV-1) and cytomegalovirus (CMV) infections. During a trial of anti-CMV retinitis therapies coadministered with antiretroviral therapy, 2-4 plasma specimens of HIV-1 RNA were collected from 36 HIV-1-infected patients receiving filgrastim to prevent neutropenia and from 36 patients not receiving filgrastim. For both groups, the crude mean and mean rate of change of HIV-1 log10 RNA levels were similar. Adjustment for covariates (CD4+ T cell lymphocytes, virus load at enrollment, level of neutropenia and antiretroviral therapy [mainly non-highly active antiretroviral therapy], and anti-CMV therapy during follow-up) resulted in a mean log10 HIV-1 RNA level for individuals receiving filgrastim versus those not receiving the drug of 5.11 versus 4.87 (P = .12) and respective log mean rates of change per month of -0.08 versus -0.21 (P = .08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads.

Original languageEnglish (US)
Pages (from-to)1013-1018
Number of pages6
JournalJournal of Infectious Diseases
Volume186
Issue number7
DOIs
StatePublished - Oct 1 2002

Fingerprint

Cytomegalovirus Retinitis
Granulocyte Colony-Stimulating Factor
HIV-1
RNA
Neutropenia
Therapeutics
Cytomegalovirus Infections
Virus Diseases
Cytomegalovirus
Filgrastim
Lymphocytes
Viruses
T-Lymphocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. / Studies of Ocular Complications of AIDS (SOCA) Research Group.

In: Journal of Infectious Diseases, Vol. 186, No. 7, 01.10.2002, p. 1013-1018.

Research output: Contribution to journalArticle

@article{fc1180a3fbf449e288dbdaa6df6df347,
title = "Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis",
abstract = "Filgrastim, or granulocyte colony-stimulating factor, reverses neutropenia associated with human immunodeficiency virus type 1 (HIV-1) and cytomegalovirus (CMV) infections. During a trial of anti-CMV retinitis therapies coadministered with antiretroviral therapy, 2-4 plasma specimens of HIV-1 RNA were collected from 36 HIV-1-infected patients receiving filgrastim to prevent neutropenia and from 36 patients not receiving filgrastim. For both groups, the crude mean and mean rate of change of HIV-1 log10 RNA levels were similar. Adjustment for covariates (CD4+ T cell lymphocytes, virus load at enrollment, level of neutropenia and antiretroviral therapy [mainly non-highly active antiretroviral therapy], and anti-CMV therapy during follow-up) resulted in a mean log10 HIV-1 RNA level for individuals receiving filgrastim versus those not receiving the drug of 5.11 versus 4.87 (P = .12) and respective log mean rates of change per month of -0.08 versus -0.21 (P = .08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads.",
author = "{Studies of Ocular Complications of AIDS (SOCA) Research Group} and Michael Davidson and Min, {Yuan I.} and Holbrook, {Janet T.} and {Van Natta}, Mark and Quinn, {Thomas C.} and Murphy, {Robert L.} and William Welch and Jabs, {Douglas A.} and Carr-Holden, {Louise M.} and Kay Doyle and Victor Fainstein and Neal Gardner and Ronald Gross and Silvia Orengo-Nania and Varsha Patel and Samo, {Tobias C.} and Shigley, {James W.} and Laura Shawver and Spencer, {Steven S.} and Mary Weinert and Dunn, {J. P.} and John Bartlett and Rebecca Becker and Jabs, {Douglas A.} and Johnson, {Daniel A.} and John Kempen and Susan LaSalvia and Jo Leslie and Janine Maenza and Tracy Miller and Neisser, {Laura G.} and Semba, {Richard D.} and Pamela Tucker and Bruce Barron and Barron Jarrott and Gholam Peyman and Dennis Swenie and Heinemann, {Murk Hein} and Roberta Janis and Bruce Polsky and Kent Sepkowitz and Friedman, {Alan H.} and Robin Ginsburg and Colette Severin and Steven Teich and Fran Welch and Ronald Rescigno and Rosa Paez-Boham and Eileen Buroff and Mendez, {Paul E.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1086/342956",
language = "English (US)",
volume = "186",
pages = "1013--1018",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis

AU - Studies of Ocular Complications of AIDS (SOCA) Research Group

AU - Davidson, Michael

AU - Min, Yuan I.

AU - Holbrook, Janet T.

AU - Van Natta, Mark

AU - Quinn, Thomas C.

AU - Murphy, Robert L.

AU - Welch, William

AU - Jabs, Douglas A.

AU - Carr-Holden, Louise M.

AU - Doyle, Kay

AU - Fainstein, Victor

AU - Gardner, Neal

AU - Gross, Ronald

AU - Orengo-Nania, Silvia

AU - Patel, Varsha

AU - Samo, Tobias C.

AU - Shigley, James W.

AU - Shawver, Laura

AU - Spencer, Steven S.

AU - Weinert, Mary

AU - Dunn, J. P.

AU - Bartlett, John

AU - Becker, Rebecca

AU - Jabs, Douglas A.

AU - Johnson, Daniel A.

AU - Kempen, John

AU - LaSalvia, Susan

AU - Leslie, Jo

AU - Maenza, Janine

AU - Miller, Tracy

AU - Neisser, Laura G.

AU - Semba, Richard D.

AU - Tucker, Pamela

AU - Barron, Bruce

AU - Jarrott, Barron

AU - Peyman, Gholam

AU - Swenie, Dennis

AU - Heinemann, Murk Hein

AU - Janis, Roberta

AU - Polsky, Bruce

AU - Sepkowitz, Kent

AU - Friedman, Alan H.

AU - Ginsburg, Robin

AU - Severin, Colette

AU - Teich, Steven

AU - Welch, Fran

AU - Rescigno, Ronald

AU - Paez-Boham, Rosa

AU - Buroff, Eileen

AU - Mendez, Paul E.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Filgrastim, or granulocyte colony-stimulating factor, reverses neutropenia associated with human immunodeficiency virus type 1 (HIV-1) and cytomegalovirus (CMV) infections. During a trial of anti-CMV retinitis therapies coadministered with antiretroviral therapy, 2-4 plasma specimens of HIV-1 RNA were collected from 36 HIV-1-infected patients receiving filgrastim to prevent neutropenia and from 36 patients not receiving filgrastim. For both groups, the crude mean and mean rate of change of HIV-1 log10 RNA levels were similar. Adjustment for covariates (CD4+ T cell lymphocytes, virus load at enrollment, level of neutropenia and antiretroviral therapy [mainly non-highly active antiretroviral therapy], and anti-CMV therapy during follow-up) resulted in a mean log10 HIV-1 RNA level for individuals receiving filgrastim versus those not receiving the drug of 5.11 versus 4.87 (P = .12) and respective log mean rates of change per month of -0.08 versus -0.21 (P = .08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads.

AB - Filgrastim, or granulocyte colony-stimulating factor, reverses neutropenia associated with human immunodeficiency virus type 1 (HIV-1) and cytomegalovirus (CMV) infections. During a trial of anti-CMV retinitis therapies coadministered with antiretroviral therapy, 2-4 plasma specimens of HIV-1 RNA were collected from 36 HIV-1-infected patients receiving filgrastim to prevent neutropenia and from 36 patients not receiving filgrastim. For both groups, the crude mean and mean rate of change of HIV-1 log10 RNA levels were similar. Adjustment for covariates (CD4+ T cell lymphocytes, virus load at enrollment, level of neutropenia and antiretroviral therapy [mainly non-highly active antiretroviral therapy], and anti-CMV therapy during follow-up) resulted in a mean log10 HIV-1 RNA level for individuals receiving filgrastim versus those not receiving the drug of 5.11 versus 4.87 (P = .12) and respective log mean rates of change per month of -0.08 versus -0.21 (P = .08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads.

UR - http://www.scopus.com/inward/record.url?scp=0036786914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036786914&partnerID=8YFLogxK

U2 - 10.1086/342956

DO - 10.1086/342956

M3 - Article

VL - 186

SP - 1013

EP - 1018

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 7

ER -